| Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. | |
| | |
MedLine Citation:
|
PMID: 22515679 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: In large randomized trials, thromboprophylaxis with fondaparinux in major orthopaedic surgery (MOS) has been shown to be superior to low molecular weight heparin (LMWH) prophylaxis with comparable safety. However, patients treated under trial conditions are different from unselected patients and efficacy and safety outcomes may be different in unselected patients in daily practice. We performed a retrospective cohort study to compare the efficacy and safety of venous thromboembolism (VTE) prophylaxis with fondaparinux or LMWH in 3896 consecutive patients undergoing major orthopaedic surgery at our centre. METHODS: All patients undergoing MOS between January 2006 and December 2009 were retrospectively analyzed using patient charts, hospital admission and discharge database, quality management database, transfusion unit database and VTE event documentation. VTE standard prophylaxis at our institution was LMWH (3000-6000 aXa units once daily) from January 2006 to December 2007 or fondaparinux 2.5 mg from January 2008 to December 2009. In these two large cohorts of unselected consecutive patients, in-hospital incidences of VTE, surgical complications, severe bleeding and death were evaluated. RESULTS: Symptomatic VTE was found in 4.1% of patients in the LMWH group (62/1495 patients; 95% CI 0.032, 0.052) compared with 5.6% of patients receiving fondaparinux (112/1994 patients, 95% CI 0.047, 0.067; P= 0.047). Distal deep vein thrombosis (DVT) was significantly more frequent in the fondaparinux group (3.9%, 95% CI 0.031, 0.048; vs. 2.5%; 95% CI 0.018, 0.034; P= 0.021). No significant differences in the rates of major VTE or death were found. Rates of severe bleeding, transfusion of RBC concentrates, plasma and platelet concentrates were comparable between both treatment groups. However, patients receiving fondaparinux had significantly lower rates of surgical revisions (1.6%, 95% CI 0.011, 0.022 vs. 3.7%, 95% CI 0.028, 0.047; P < 0.001). Multivariate analysis revealed previous VTE (HR 18.2, 95% CI 11.6, 28.5; P < 0.001) and female gender (HR 1.9, 95% CI 1.3, 2.7; P < 0.001), but not fondaparinux prophylaxis (HR1.3, 95% CI 0.9, 1.7; P= 0.184) to be associated with significantly increased VTE risk. DISCUSSION: Thromboprophylaxis with fondaparinux is less effective to prevent distal VTE than LMWH in unselected patients undergoing MOS, but is equally effective with regard to rates of major VTE and death. However, differences in efficacy of LMWH or fondaparinux are of little relevance compared with a history of VTE or female gender, which were found to be the main VTE risk factors in MOS. The safety profile of fondaparinux was comparable with LMWH with regard to rates of severe bleeding complications, but patients receiving fondaparinux had significantly less surgical complications requiring surgical revisions. Both our efficacy and safety findings differ from data derived from large phase III trials testing fondaparinux against LMWH in MOS, where overall rates of symptomatic VTE were lower and the safety profile of fondaparinux was different. CONCLUSION: We conclude that the strict patient selection and surveillance in phase-III trials results in lower VTE and bleeding event rates compared with unselected routine patients. Consequently, the efficacy and safety profile of thromboprophylaxis regimens needs to be confirmed in large registries or phase IV trials of unselected patients. |
| | |
Authors:
|
Lars Donath; Jörg Lützner; Sebastian Werth; Eberhard Kuhlisch; Albrecht Hartmann; Klaus-Peter Günther; Norbert Weiss; Jan Beyer-Westendorf |
Related Documents
:
|
19490179 - Impact of different patterns of nonadherence on the outcome of highly active antiretrov... 22519759 - Oral anticoagulant therapy in italian patients 80 years of age or older with atrial fib... 16078339 - Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of my... 22828169 - Treatment of hyperprolactinemia: a systematic review and meta-analysis. 22914349 - The "prometeo" study: online collection of clinical data and outcome of italian patient... 22380529 - Randomised clinical trial: the safety and efficacy of long-acting octreotide in patient... 11449589 - A simplified approach to temporary ddd pacing using a single lead, balloon-tipped cathe... 15752679 - Long-term azitromycin treatment of cystic fibrosis patients with chronic pseudomonas ae... 18647499 - Therapeutic effect analysis of acute traumatic brain injuries. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 74 ISSN: 1365-2125 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2012 Dec |
Date Detail:
|
Created Date: 2012-11-13 Completed Date: 2013-04-16 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 947-58 Citation Subset: IM |
Copyright Information:
|
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society. |
Affiliation:
|
Centre for Vascular Medicine and Department of Medicine III, Division of Angiology, Dresden, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anticoagulants / adverse effects, therapeutic use* Cohort Studies Female Heparin, Low-Molecular-Weight / adverse effects, therapeutic use* Humans Male Middle Aged Orthopedic Procedures* Polysaccharides / adverse effects, therapeutic use* Postoperative Complications / prevention & control Randomized Controlled Trials as Topic Registries Retrospective Studies Treatment Outcome Venous Thromboembolism / prevention & control* Venous Thrombosis / prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/Polysaccharides; J177FOW5JL/fondaparinux |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Psychophysiological responses to cooperation: The role of outcome and gender.
Next Document: Si-Compatible Cleaning Process for Graphene Using Low Density Inductively Coupled Plasma.